Q4 2025 · 13F-HR
BVF INC/ILholdings as filed
Filed 2026-02-17 · accession 0000921895-26-000449
$2.97B
Reported value
41
Positions
2025-12-31
Period end
The Brief · BVF INC/IL · Q4 2025
AI · grounded in 13F
BVF INC/IL closed its position in PTGX, reducing exposure by $170.1M. The fund also exited positions in CDTX for $135.4M and CELC for $32.5M. New capital was deployed into IRON with a $51.6M investment and IVVD with a $48.2M investment. Additionally, the fund increased its share count in XNCR by 160.3%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $428.2M | 14.4% | 5,502,710 | Common | SHARED |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $267.4M | 9.00% | 3,356,782 | Common | SHARED |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $260.3M | 8.76% | 19,751,284 | Common | SHARED |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $242.0M | 8.15% | 3,479,022 | Common | SHARED |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $132.4M | 4.46% | 5,295,893 | Common | SHARED |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $118.1M | 3.98% | 1,495,290 | Common | SHARED |
| G3855L106 | GHRS | GH RESEARCH PLC | $112.1M | 3.77% | 8,827,712 | Common | SHARED |
| 98401F105 | XNCR | XENCOR INC | $109.2M | 3.68% | 7,133,720 | Common | SHARED |
| 98985Y108 | ZYME | ZYMEWORKS INC | $103.7M | 3.49% | 3,938,641 | Common | SHARED |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $92.0M | 3.10% | 879,009 | Common | SHARED |
| 50127T109 | KURA | KURA ONCOLOGY INC | $89.5M | 3.01% | 8,617,162 | Common | SHARED |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $71.9M | 2.42% | 2,265,674 | Common | SHARED |
| 98419J206 | XOMA | XOMA ROYALTY CORPORATION | $68.9M | 2.32% | 2,590,303 | Common | SHARED |
| 00370M103 | ABVX | ABIVAX SA | $68.5M | 2.31% | 508,031 | Common | SHARED |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $65.9M | 2.22% | 1,559,595 | Common | SHARED |
| H00263105 | ACIU | AC IMMUNE SA | $62.2M | 2.10% | 19,822,436 | Common | SHARED |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $60.1M | 2.02% | 3,835,886 | Common | SHARED |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $59.5M | 2.00% | 5,750,683 | Common | SHARED |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $55.9M | 1.88% | 2,127,665 | Common | SHARED |
| 254604101 | IRON | DISC MEDICINE INC | $51.6M | 1.74% | 650,000 | Common | SHARED |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $50.3M | 1.69% | 1,488,975 | Common | SHARED |
| 00534A102 | IVVD | INVIVYD INC | $48.2M | 1.62% | 19,525,000 | Common | SHARED |
| 81734D104 | SEPN | SEPTERNA INC | $48.0M | 1.61% | 1,720,782 | Common | SHARED |
| 03589W102 | ANNX | ANNEXON INC | $45.8M | 1.54% | 9,128,080 | Common | SHARED |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $41.7M | 1.40% | 7,764,842 | Common | SHARED |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $34.7M | 1.17% | 4,629,289 | Common | SHARED |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $32.6M | 1.10% | 2,748,763 | Common | SHARED |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $28.6M | 0.96% | 5,302,000 | Common | SHARED |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $26.9M | 0.90% | 10,333,600 | Common | SHARED |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $24.6M | 0.83% | 1,355,257 | Common | SHARED |
| 713317105 | PEPG | PEPGEN INC | $12.5M | 0.42% | 1,915,000 | Common | SHARED |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $9.5M | 0.32% | 6,293,282 | Common | SHARED |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $8.9M | 0.30% | 2,233,742 | Common | SHARED |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $8.4M | 0.28% | 45,757 | Common | SHARED |
| 60853G106 | MOLN | MOLECULAR PARTNERS AG | $5.8M | 0.20% | 1,353,968 | Common | SHARED |
| 45175G207 | IMA | IMAGENEBIO INC | $5.5M | 0.19% | 802,102 | Common | SHARED |
| 89854M101 | TCRX | TSCAN THERAPEUTICS INC | $5.2M | 0.18% | 5,226,074 | Common | SHARED |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $4.1M | 0.14% | 339,549 | Common | SHARED |
| 4525EP101 | VTLUSD | IMMUNIC INC | $4.1M | 0.14% | 7,652,972 | Common | SHARED |
| 46124U107 | IVA | INVENTIVA SA | $3.2M | 0.11% | 686,040 | Common | SHARED |
| 29286M113 | — | ENGENE HOLDINGS INC | $2.4M | 0.08% | 945,402 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.